
abbyie

Find answers that make life better for patients and our world

Antonio Della Crocce General Manager CZ&SK

People.
Passion.
Possibilities.®



AbbVie creates medicines and solutions that put impact first — for patients, communities and our world.

AbbVie was founded January 2, 2013

50K+ employees working in **70+ countries**

\$55B+ invested*
to research, develop
and discover new
medicines since
AbbVie was founded

*Adjusted R&D investment, cumulative since inception

~20 countries with R&D and/or manufacturing facilities

From treating 20 conditions across all stages of life in 2013 to more than 75+ conditions 10 years later

people are treated every year, including more than 16 million people in the United States

25 major product or indication approvals since 2013 including 4 major product or indication approvals in 2022

175+

countries where AbbVie products help people and patients Recognized for being a good corporate citizen and for our contributions to society and business performance

We foster a culture of curiosity True innovation is impossible without a diverse and collaborative team.

Our Principles guide and unite us all, empowering our employees and strengthening our partnerships.

Our Principles

- Transforming Lives
- Acting with Integrity
- Driving Innovation
- Embracing Diversity & Inclusion
- Serving the Community

250+ active external innovation partners

We align our capabilities to conduct groundbreaking science to discover and develop innovative medicines.

57%

of employees in STEM-related positions are women.

37%*

of employees are from underrepresented populations. *U.S. only statistic







We have received more than 40 Great Place to Work and Top Employer rankings globally.

We solve the tough challenges Combining science and support, we work to discover and develop life-changing medicines and first-in-kind solutions.

R&D investment

\$7.1B

In adjusted research & development investment in 2022

Clinical trials

240+ clinical trials
in
55+ countries
with more than
9K study sites

Our pipeline

80+

Compounds, devices or indications in the AbbVie pipeline

~50

In mid- and late-stage development

New study starts

110+

New study starts planned for 2023

We lead with purpose Doing the right thing means showing up to each moment with integrity and care. The choices we make deliver a lasting impact for patients, families and communities.

198K+

patients received free AbbVie medicine in 2022 – Industry-leading patient assistance program

200K+

patients and health care providers supported through independent education grants

>530

patient support programs to help patients access and manage their prescribed treatment journey

\$21.7M

raised for 12,600 charities through our Employee Giving Campaign We focus on a **core set of therapeutic areas** — ones where we've **proven our expertise** and where we have **even greater potential** to improve how diseases and conditions are managed.



We are the industry leader in immunology

We are applying our significant expertise in immunology to invest in and advance care for areas of high disease burden and unmet need, working to ensure as many patients as possible get the solution they need with our transformative immunology therapies.



3

In market products and 5 investigational medicines



17

Approved indications with 5 additional in development



>1MM

patients worldwide being treated with AbbVie immunology products



25 years

Immunology experience



We pioneer research to transform standards of care across oncology


We're committed to advancing a dynamic pipeline and continuing to drive solutions for blood cancer.

Pipeline areas of biology

- Immuno-oncology
- Tumor dependency

Key technologies

- Bispecific antibodies
- Targeted protein degradation
- Antibody drug conjugates
- Cellular therapies
- Small molecules



Oncology highlights

Developing **new technologies and medicines** have allowed us to **reimagine patient treatments for solid tumors and blood cancers.**



20+

investigational medicines as potential treatment options



8

transformative oncology partnerships



300+

active clinical trials around the world



3

first-in-class oncology medicines*

*Includes 1 2023 approval.



We make a lasting impact for patients in neuroscience

We're researching and developing new, innovative, disease-modifying solutions to address some of the most difficult-to-treat neurodegenerative diseases.

Research interests

- New disease modification approaches
- Genetic, molecular and physiological insights
- Enhancing the treatment landscape for better patient outcomes

Disease areas

- Alzheimer's disease
- Depression and Anxiety
- Migraine
- Parkinson's disease
- Schizophrenia and Bipolar
- Spasticity, cervical dystonia



We help those living with compromised vision

We continue to pioneer research that reduces the treatment burden for patients, with a focus on the areas of greatest need from the front to the back of the eye.

Disease areas

- Age-related retinal diseases, including age-related macular degeneration
- Chronic dry eye disease
- Corneal regeneration
- Diabetic macular edema
- Glaucoma
- Refractive disorders, including presbyopia and myopia
- Retinal vein occlusion



75 years in eye care125 eye care products

Other areas highlights

Our scientific talent is as diverse as the diseases we study.

Beyond our work in virology and anti-infectives, we have established research teams with the ultimate goal of improving the quality of life for patients.

We focus on diseases with high unmet need.





Endocrinology, focused on conditions linked to hormonal disorders, including hyperthyroidism and heavy menstrual bleeding due to uterine fibroids in pre-menopausal women



Therapeutic neurotoxins, looking at postoperative and atrial fibrillation and overactive bladder



Gastrointestinal tract disorders not related to autoimmune disorders, like pancreatic enzyme replacement therapy and irritable bowel syndrome with constipation (IBS-C)

We aim to empower confidence, decades after pioneering the field of aesthetic medicine

As a global leader in each major medical aesthetics category spanning injectables, body contouring, skincare and plastics and regenerative medicine, we have the most comprehensive science-based product offerings available and are the only company that serve the full spectrum of aesthetics needs globally.



Allergan Aesthetics highlights

Pipeline focus areas

- Neurotoxins
- Soft tissue fillers
- Non-invasive body contouring
- Plastic surgery and regenerative medicine
- Topical skincare



90+

Markets with Allergan Aesthetics presence



~60

programs in early research and late-stage global pipeline



3,300+

Colleagues around the world



56K

HCP participants in U.S. training programs



We are building a more sustainable future for generations to come.

Advancing environmental, social and governance (ESG) initiatives contributes to the sustainable growth of our company and helps us create positive impact for generations to come.

ESG Pillars

We discover and deliver innovative medicines that solve serious health issues.

We unlock the full potential of our diverse and talented teams and partners to deliver today and into the future.

We innovate with integrity and intention to advance long-term patient health and business resiliency.



We are proud to recognized for our strong commitments



Workplace & Diversity



FORTUNE 100 Best

Companies to Work For®

Great Place to Work's World's Best WorkplacesTM

Human Rights Campaign Corporate Equality Index

Seramount "100 Best Companies" - #1 in 2022



Business Performance

FORTUNE 500

FORTUNE World's Most Admired Companies



Environment, Social and Governance

Dow Jones Sustainability World and North America Indices

Top 1% S&P Global ESG Score: Top Biotech industry score for S&P Global ESG Yearbook Rankings

EcoVadis Corporate Social Responsibility Assessment Gold Medal

FTSE4Good Index

AbbVie ranked on the 2022 Purpose Power Index

3BL Media "100 Best Corporate Citizens"



Our state-of-the-art R&D facilities* span the globe



abbyie